Work

Abstract PS4-07-21: Safety and Clinical Outcomes of Pembrolizumab Standard Dosing Versus Extended-Interval Dosing in Patients with Breast Cancer

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps4-07-21

Authors: A. LeVee, A. Kordic, N. Ruel, J. Mortimer, I. Kang, H. McArthur, M. G. Lechner, K. Tsai

Institutions: University of California, Los Angeles, City Of Hope National Medical Center, City of Hope, The University of Texas Southwestern Medical Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129745701

Cites:

Cited by:

Related to: